

FEB 24 1965

OAK RIDGE NATIONAL LABORATORY

723942

OPERATED BY  
UNION CARBIDE CORPORATION  
NUCLEAR DIVISION



POST OFFICE BOX X  
OAK RIDGE, TENNESSEE 37831

CODE NO.  
R-1d

February 23, 1965

Dr. Gould A. Andrews  
Medical Division  
Oak Ridge Institute of Nuclear  
Studies, Inc.  
P. O. Box 117  
Oak Ridge, Tennessee 37831

Dear Dr. Andrews:

Thank you for your letter of February 12. We are very much encouraged that you are ready to go ahead on human studies of metabolism of various radionuclides. We will be very much pleased to cooperate in every way to further these studies, and we will be glad to attempt to supply the source materials for these studies.

It is evident that we should consider very carefully what materials should be used and what the schedule of administration and collection of specimens might be. This, in turn, depends on a careful consideration of the objectives. In our case our interest is primarily in the metabolic aspects, and we would urge that the levels be low enough that no detectable biological effects are expected.

I will be away from my office for approximately two weeks, and, if possible, I would hope that preliminary discussions could be started in my absence. I suggest that you or others of the ORINS staff contact Dr. S. R. Bernard of the Health Physics Division to begin discussions on these questions.

Very sincerely yours,

Walter S. Snyder, Assistant Director  
Health Physics Division

REPOSITORY MMES-ORNL  
COLLECTION 4500S AHIC  
BOX No. KZ Morgan  
FOLDER R-1d  
cc: S. R. Bernard  
K. Z. Morgan

1168240

WSS:ss

A-00542

Human Studies Project

# OAK RIDGE INSTITUTE OF NUCLEAR STUDIES

INCORPORATED  
P. O. BOX 117

OAK RIDGE, TENNESSEE 37831

MEDICAL DIVISION

February 12, 1965

AREA CODE 615  
TELEPHONE 483-8411

FEB 16 1965

Dr. Walter S. Snyder  
Bldg. 4500-S  
Oak Ridge National Laboratory  
Oak Ridge, Tennessee

Dear Doctor Snyder:

Since our discussion regarding the administering of trans-uranium elements to patients sometime ago, we have carefully considered the problems that would be involved regarding the control of the material, its administration, and sample collection. Some minor modifications of our present procedures will be required because of the greater toxicity of the transuranium elements compared to the materials that we normally handle.

We intend to select patients very carefully for this program and to give attention to the ethical and legal aspects of this type of study.

In the fairly near future we expect to be ready to begin this program. We wonder if you are in a position to help us obtain suitable preparations of these radioactive elements. It would be desirable to have the material in a form that it could be injected whenever a patient that might be used in the program becomes available. We would like to know as much as possible about the chemistry of the material; such as, whether it is a colloid, pH, and if any chemical toxicological effects might be expected.

If we can be of assistance in helping you to obtain this material, please request it of us.

Sincerely yours,



Gould A. Andrews, M.D.

GAA/pe

1168241